P297 WATER-SOLUBLE FULLERENE (C60) PREVENTS DEGENERATION OF ARTICULAR CARTILAGE IN OSTEOARTHRITIS  by Yudoh, K. et al.
S162 Poster Presentations
creased release of high molecular weight HA in the synovial fluid
and enhanced aggregating potential for cartilage proteoglycans.
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MANAGEMENT (PAFORM) STUDY. A RANDOMISED
CONTROLLED CLINICAL TRIAL EVALUATING
HYDROTHERAPY AND TAI CHI CLASSES
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Purpose: To determine whether Tai Chi or hydrotherapy classes
for people with chronic symptomatic hip or knee osteoarthritis
(OA) can result in measurable clinical benefits.
Methods: A randomised controlled trial was conducted among
152 people, aged 59 years and over, with chronic symptomatic
hip or knee OA. Participants were randomly allocated for 12
weeks to hydrotherapy classes (n=55), Tai Chi classes (n=56) or
waiting list control (n=41). Outcomes were assessed at 12 weeks
(post treatment) and 24 weeks (sustainability) after randomisa-
tion and included pain and physical function (WOMAC), general
health status (SF-12v2), psychological well being and physical
performance (‘up and go’, 50 ft walk time, timed stair climb).
Results: At the 12 week post treatment assessment, 49%
(n=27), 34% (n=19) and 15% (n=6) of participants allocated
to hydrotherapy, Tai Chi and control group, respectively, were
treatment responders according to OMERACT-OARSI responder
criteria D. The difference in treatment responder rate between
the three allocation groups was significant (chi-squared=12.4, df
= 2, p=0.002). Compared with control, participants allocated to
hydrotherapy classes demonstrated mean improvements (95%
confidence interval) of 6.5 (0.4 to 12.7) and 10.5 (3.6 to 14.5)
for pain and physical function scores (range 0-100), respectively,
while participants allocated to Tai Chi classes demonstrated im-
provements of 5.2 (-0.8 to 11.1) and 9.7 (2.8 to 16.7). The 95%
CI for treatment effect sizes for physical function for hydrotherapy
or Tai Chi classes ranged from moderate to large (.50 to .76).
Both class allocations achieved significant improvements in the
SF-12 physical component summary score, but only allocation to
hydrotherapy classes achieved significant improvements in the
measures of physical performance. All significant improvements
were sustained at 24 weeks after randomisation. In this almost
exclusively Caucasian sample, class attendance was higher for
hydrotherapy with 81% attending at least half of the available 24
classes, compared with 61% for Tai Chi.
Conclusions: Access to either hydrotherapy or Tai Chi classes
can provide sustained improvements in pain and physical func-
tion for many older, sedentary people with chronic symptomatic
hip or knee OA. The improvements achieved in physical function
were greater than those demonstrated for traditional land-based
exercise programs.
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THE EFFICACY OF HYLAN G-F 20 AND SODIUM
HYALURONATE IN THE TREATMENT OF
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RANDOMIZED DOUBLE BLINDED CLINICAL TRIAL
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Purpose: To compare the clinical effectiveness, functional out-
come and patient satisfaction following intra articular injection
with Synvisc® and Hyalgan® in patients with osteoarthritis (OA)
of the knee
Methods: 356 consecutive patients with OA of the knee were
randomized into two groups to receive Hylan G-F-20 -Synvisc
(n=184) or Sodium Hyaluronate -Hyalgan (n=172). Weight bear-
ing radiographs were reviewed at baseline to grade the degree
of OA using the Kellgren-Lawrence system. All patients were
prospectively reviewed by blinded independent assessors at pre
injection, 6 weeks, 3, 6, 12 months. Knee pain and patient sat-
isfaction was measured on a VAS (0-10, 10 as worst pain).
Functional outcome was assessed using WOMAC, UCLA, Teg-
ner, Oxford knee score and EuroQol- 5D scores. Mean follow up
was 12 months
Results: The mean age of the randomised patients was 66.7 yrs.
Patients in both groups predominantly had grade III OA (Synvisc-
61% and Hyalgan-59%). There were no significant differences in
the age, sex and degree of OA between the two groups. Knee
pain on VAS improved from 6.7 to 3.2 by 6 weeks (p=0.02) and
was sustained until 12 months (3.7, p=0.04) with Synvisc. In
the Hyalgan group, pain improved from 6.6 to 5.7 at 6 weeks
(p>0.05) and to 4.1 at 3 months (p=0.04) but was sustained only
until 6 months (5.9, p>0.05). Improvements in the WOMAC pain
and physical activity subscales were significantly superior in the
Synvisc group at 3 months (p=0.02), 6 months (p=0.01) and 12
months (p=0.02). Similarly, the Tegner, UCLA and Oxford knee
scores were significantly better in the Synvisc group at 6 weeks
(p=0.02) and 6 months (p=0.03) and 12 months (p=0.04) post
injection whilst there was no difference between the groups at 3
months. There was no significant difference in the EQ-5D scores
at 6 weeks, and 3 months between the two groups. The EQ-5D
description scores were higher in the Synvisc group at 6 months
(p=0.03) and 1 year (p=0.04). General patient satisfaction was
better in the Synvisc group at all times although statistically
significant at 3 months (p=0.01) and 6 months (p=0.02). There
was local increase in knee pain in one patient who received
Synvisc, which settled by 4 weeks. Patient compliance was
99.2% in the Synvisc group as compared to 92.2% in the Hyalgan
group due to the number of recommended injections. There was
no difference in the cost of the drugs, but the total treatment cost
was 23% more in the Hyalgan group due to the two additional
visits to complete the course of treatment
Conclusions: Although both treatments offered significant pain
reduction, it was achieved earlier and sustained for a longer pe-
riod in patients with Synvisc. Patients treated with Synvisc have
demonstrated an early increase in activity levels as evidenced
by the WOMAC, UCLA and Tegner scores. Both treatments were
well tolerated, however, a local reaction of pseudo sepsis was ob-
served with Synvisc in one patient. The total treatment cost, both
for the patient and the hospital are higher with Hyalgan. From
this study, it appears that the clinical effectiveness and general
patient satisfaction are better amongst patients who received
Synvisc
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Purpose: Recently, attention has been attracted that oxidative
stress and its related chondrocyte aging have an important role
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in the pathogenesis of osteoarthritis (OA). In our previous study,
we demonstrated that oxidative stress induced the features of
chondrocyte senescence during the progression of OA.
Fullerene (C60) is spherical carbon molecules with a unique
cage structure. C60 is characterized as a strong radical sponge.
Recent report revealed that this compound has a high reactivity
with oxygen free radicals and their potential activity as free
radical scavengers. It has been demonstrated that C60 inhibits
neuronal apoptosis by scavenging oxygen reactive species. Also,
it has been demonstrated that C60 protects against human skin
keratinocytes from cell death after UV stress.
As above mentioned, there is evidence for oxidative damage by
reactive oxygen speaceis in OA cartilage. It is well known that ox-
idative stress (oxygen homeostasis and its down-regulation) are
closely involved in the pathogenesis of OA. Exploitation of C60
molecule could lead to the definition of new therapeutic strate-
gies in the prevention of both chondrocyte aging and cartilage
degeneration.
To prevent the degeneration of articular cartilage in OA, we
focused on C60, which acts a strong free radical scavenger, as
an anti-oxidative agent. We studied whether or not water-soluble
fullerene has a potential as a protective agent against catabolic
stress-induced degeneration of articular cartilage both in vitro
and in vivo.
Methods: i) In the presence or absence of water soluble C60
(50, 100 μM), human chondrocytes were incubated with IL-1 β
(10 ng/ml) or H2O2 (100 μM). After the incubation period, chon-
drocyte activity ((MMP-1, -3, -13 production, type II collagen and
aggrecan production, cellular apoptosis, cellular senescence)
was analyzed.
ii) OA rabbit model was produced by resection of both the anterior
cruciate ligament and the medial collateral ligament. 32 rabbits
(New Zealand White rabbits) were divided into 4 subgroups; 0.1
μM C60-treated group, 1.0 μM C60-treated group, 10.0 μM C60-
treated group, and 40.0 μM C60-treated group. In each rabbit
after surgical treatment, the left knee joint was treated by an
intra-articular injection of appropriate water-soluble C60 (2.0 ml)
once a week over 4 or 8 weeks. The right knee joint was also
treated by an intra-articular injection of 50% polyethyleneglycol
(2.0 ml) as a control once a week over 4 or 8 weeks. The rabbits
were euthanized 4 and 8 weeks after surgery and both knee
joints were harvested. Bone and cartilage tissue blocked were
prepared for histological analysis.
Results: C60 (50, 100 μM) inhibited the catabolic stress-induced
production of matrix degrading enzymes (MMP-1,-3, -13), apop-
tosis and premature senescence of chondrocytes in vitro. In
OA rabbit model, treatment with water-soluble C60 significantly
reduced the degeneration of articular cartilage, whereas the con-
trol knee joints showed the progression of cartilage degeneration
with time. We also observed the inhibitory effect of C60 on the
cartilage degeneration in a dose dependent manner in OA rabbit
model.
Conclusions: We confirmed that C60 inhibited the catabolic
stress-induced production of matrix degrading enzymes, down-
regulated production of matrix proteins, cellular senescence and
apoptosis in cultured chondrocytes in vitro. Also, our in vivo
study with OA rat model indicate that C60 fullerene may be a
therapeutic agent to protect the articular cartilage with advance
of cartilage degeneration in OA.
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THE EFFECTS OF FOOTWEAR ON DYNAMIC LOADING
OF THE KNEE IN HEALTHY SUBJECTS
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Purpose: Dynamic joint loading is an important factor in the
pathophysiology of osteoarthritis (OA) of the knee, and the preva-
lence and progression of knee OA are known to be associated
with high dynamic loading (i.e. peak external knee adduction
moment). We have previously demonstrated that in subjects
with knee OA, walking barefoot significantly decreases the peak
external knee adduction moment compared to walking with stan-
dard walking shoes (Arthritis Rheum, in press). Subsequently,
we designed a shoe to incorporate the essential "unloading"
characteristics of barefoot walking. Here, we test the hypothesis
that barefoot walking reduces knee loading in normal healthy
individuals as well as in OA, and thus that normal subjects will
exhibit significantly reduced knee loading when walking barefoot
and when walking with our "unloading" shoes compared to their
"usual" walking shoes.
Methods: Twenty-six normal subjects underwent gait analyses
of their dominant limb using an optoelectronic camera system
and a multi-component force plate. Subjects were evaluated for
gait while wearing their self-selected "usual" walking shoes. In
addition, all of the subjects underwent gait analyses while bare-
foot and 19 underwent analyses with the "unloading" shoes. In
each case, subjects were permitted to acclimate to the new con-
dition prior to gait testing. Subjects walked at their normal walk-
ing speed, and comparisons were performed on runs matched
for speed. The peak external knee adduction moment (%body
weight * height) was calculated at the knee and used as the pri-
mary endpoint. Paired t-tests were used to compare differences
in the moment during the different "footwear" conditions.
Results: 18 females and 8 males were evaluated, with mean age
(±SD) of 42±13 years. There were no significant differences in
speed during the three walking conditions. Overall, a significant
reduction in the peak external knee adduction moment was noted
during barefoot walking (2.0 ±0.7 vs 2.3±0.8, p=0.023) and while
walking with the "unloading" shoe (2.0±0.9 vs 2.3±0.8, p=0.009)
compared to "usual" walking shoes. These results corresponded
to a 13% reduction the peak external knee adduction moment
during the barefoot and "unloading" shoe conditions.
Conclusions: This study demonstrates that the reduction in
medial knee loading during barefoot walking that was previously
observed in knee OA patients is a general phenomenon that also
applies to normal individuals. Furthermore, a shoe designed to
incorporate the biomechanical advantages of barefoot walking
effectively reduces the dynamic knee loads in normal individuals
during gait relative to loading with usual footwear. In light of
these findings in normal individuals, closer examination of the
design and biomechanical effects of modern footwear on lower
extremity joint loading is warranted, both in healthy individuals
who may be at risk for OA as well as in those with established
OA.
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Purpose: The Glucosamine/chondroitin Arthritis Intervention
Trial (GAIT) was a double-blind, placebo-controlled, random-
ized, clinical trial comparing glucosamine (G), chondroitin sulfate
(CS), the combination of G and CS, and celecoxib (CE) to
placebo (PL). No treatment differences were observed among
the dietary supplements in the primary analysis. We report treat-
ment effects in a subgroup analysis of patients with potentially
milder disease.
Methods: GAIT patients were required to have clinical and ra-
diographic OA and a summed WOMAC Pain score of 125-400
